CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2005-02-23): New scoring system points to liver cancer outcome

Epidemiology

New scoring system points to liver cancer outcome

Last Updated: 2005-02-23 14:41:12 -0400 (Reuters Health)

NEW YORK (Reuters Health) - The Tokyo score, a novel prognostic system, accurately predicts outcome in Japanese patients with hepatocellular carcinoma (HCC), according to a report in the March issue of Gut.

Dr. R. Tateishi and colleagues from University of Tokyo developed the score, which ranges from 0 to 6 and involves serum albumin, bilirubin, and size and number of tumors.

The investigators tested its validity in 403 consecutive patients with HCC treated by percutaneous ablation and in 203 patients who underwent hepatectomy.

Five-year survival rates fell significantly with increases in Tokyo score, the authors report. They declined from 78.7% for patients with Tokyo scores of 0, to 14.3% for patients with Tokyo scores between 4 and 6.

In Cox proportional hazard regression models, the Tokyo score proved equal to the Cancer of the Liver Italian Program (CLIP) scoring system for HCC, and better than Barcelona Clinic Liver Cancer (BCLC) staging. Overall, the researchers note, the Tokyo score appeared to be more informative than the other two systems.

"We established the Tokyo score by analyzing survival time among HCC patients treated with medical ablation and validated it in patients who underwent surgical resection," the authors conclude. "The Tokyo score may be useful in predicting the prognosis of HCC patients who are candidates for these curative treatments."

In an accompanying editorial, Dr. S. Ryder from Queen's Medical Centre, Nottingham, UK notes that "it should be emphasized that these are not natural history based models; almost all patients had therapy and some patients had more than one treatment modality."

Thus he points out that the outcome "is subject to the impact of many treatment related effects on survival which may not be reproducible in standard clinical practice."

Gut 2005;54:419-425,328-329.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.